title: Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
abstract: BACKGROUND
  Pretreatment cytogenetics are not routinely used to predict patient outcomes in mantle cell lymphoma (MCL). Based on the prognostic utility of cytogenetics in other diseases, we reviewed the effect of a complex karyotype (CK) in MCL.
  
  
  METHODS
  We included patients evaluated between November, 2002, and May, 2011. Those with ≥ 3 chromosomal abnormalities on a pre-treatment cytogenetic evaluation were defined as CK. Demographic, clinical, and survival differences between patients with CK and non-CK (NCK) were assessed.
  
  
  RESULTS
  Of 80 patients, 32 (40%) had CK, which was associated with high-risk clinical risk factors. Therapy did not differ between the groups, nor did rate of autologous stem cell transplant (ASCT). The 2-year progression-free survival (PFS) estimates were 70% and 48% for patients with NCK and CK, respectively (P = .02). Two-year overall survival (OS) estimates were also greater in those with NCK versus CK (85% vs. 58%; P = .02). When controlling for high-risk Mantle Cell Lymphoma International Prognostic Index (MIPI) score (P = .006), bulky disease (P = .01), and ASCT in first remission (P = .01), CK was not significantly associated with PFS (P = .18).
  
  
  CONCLUSIONS
  CK is associated with shortened PFS and OS in MCL but has not been demonstrated to be prognostic independent of other variables in this series.
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH. Electronic address: Jonathon.cohen@emory.edu.
authors: Jonathon B
authors: JB
authors: Cohen
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Amy S
authors: AS
authors: Ruppert
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH; Department of Pathology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Nyla A
authors: NA
authors: Heerema
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Leslie A
authors: LA
authors: Andritsos
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Jeffrey A
authors: JA
authors: Jones
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Pierluigi
authors: P
authors: Porcu
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Robert
authors: R
authors: Baiocchi
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Beth A
authors: BA
authors: Christian
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: John C
authors: JC
authors: Byrd
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Joseph
authors: J
authors: Flynn
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Sam
authors: S
authors: Penza
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Steven M
authors: SM
authors: Devine
authors: Division of Hematology, The Ohio State University-James Comprehensive Cancer Center, Columbus, OH.
authors: Kristie A
authors: KA
authors: Blum
mesh_terms: D059786:Abnormal Karyotype; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D020522:Lymphoma, Mantle-Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D016896:Treatment Outcome
keywords: Cytogenetics; Non-Hodgkin lymphoma; Outcomes; Prognosis; del(17p)